Gemmus is a privately held biotechnology company focused on the development of innovative pharmaceutical products for the treatment of influenza and other viral infectious diseases. Using a novel, host-directed approach, we target the underlying cause of debilitating symptoms associated with influenza and ‘influenza-like-illness’ (ILI) by modulating the natural immune response to the disease. We are committed to developing “first-in-class, best-in-class” products that meet a major medical need.
Gemmus Pharma was founded in 2007 to commercialize in-licensed technology from a major pharmaceutical company. Gemmus’ lead candidate is a cardiovascular drug currently marketed in Asia that has been repurposed for use as a treatment for influenza. Gemmus has received support from the National Institute of Allergy and Infectious Disease (NIAID) and has completed a Series A round. The company has applied for and received an SBIR(NIH) and a QTDP competitive grant. Gemmus plans to file an investigational new drug (IND) application with the FDA for treatment of influenza infections in 2014.
Gemmus Pharma was founded in 2007 to commercialize in-licensed technology from a major pharmaceutical company. Gemmus’ lead candidate is a cardiovascular drug currently marketed in Asia that has been repurposed for use as a treatment for influenza. Gemmus has received support from the National Institute of Allergy and Infectious Disease (NIAID) and has completed a Series A round. The company has applied for and received an SBIR(NIH) and a QTDP competitive grant. Gemmus plans to file an investigational new drug (IND) application with the FDA for treatment of influenza infections in 2014.
Location: United States, California, San Francisco
Employees: 11-50
Total raised: $3.3M
Founded date: 2007
Investors 1
| Date | Name | Website |
| - | Tech Coast... | techcoasta... |
Funding Rounds 1
| Date | Series | Amount | Investors |
| 13.05.2014 | Series B | $3.3M | - |
Mentions in press and media 5
| Date | Title | Description |
| 13.05.2014 | Gemmus Pharma Closes $3.3M Series B Funding | Gemmus Pharma, a San Francisco, California-based biotechnology company developing an improved host-targeted treatment for flu, closed a $3.3m Series B funding. Backers included the Life Science Angels (LSA), BlueTree Allied Angels, The Ange... |
| 28.06.2012 | Gemmus Pharma Closes Series A Funding | Gemmus Pharma Inc., a San Francisco, CA-based biotechnology company developing an improved host-targeted treatment for influenza, has closed on a Series A funding. The amount was not disclosed. The round was led by the Life Science Angels (... |
| 28.06.2012 | Gemmus Pharma Closes Series A | SAN FRANCISCO, CA, Privately held biotechnology company developing an improved host-targeted treatment for influenza, raised Series A funded by a syndicate of angel groups led by the Life Science Angels. >> Click here for more fund... |
| - | BlueTree Venture Fund Invests in Gemmus Pharma | BlueTree Venture Fund, a Pittsburgh-based venture capital firm recently invested in Gemmus Pharma, a San Francisco-based company focused on the innovative development of pharmaceuticals for influenza and other viral infectious diseases. |
| - | Gemmus News: Gemmus Pharma Announces FDA Acceptance of IND Application for GP1681 – a Novel Host-based Drug Candidate for Influenza | San Francisco, CA, May 11, 2014— Gemmus Pharma, Inc., a privately-held pharmaceutical company developing innovative therapies to treat influenza, announced today that its Investigational New Drug Application (IND) for GP1681, the company’s ... |